{"filing":{"accession_number":"0001193125-26-335368","cik":"0001709941","ticker":"BIOA","company_name":"BioAge Labs, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"bioa-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-20260805.htm"},"events":[{"id":24167,"run_id":21878,"accession_number":"0001193125-26-335368","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"BioAge Labs issued a press release on August 5, 2026 announcing its financial results for the second quarter ended June 30, 2026, including collaboration revenue of $2.4 million, R\u0026D expenses of $24.4 million, and a net loss of $26.1 million ($0.58 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and material business updates regarding clinical trial progress for lead candidate BGE-102.","company_name":"BioAge Labs, Inc.","ticker":"BIOA","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":24597,"accession_number":"0001193125-26-335368","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BioAge Labs issued a press release on August 5, 2026 announcing its financial results for the second quarter ended June 30, 2026, including collaboration revenue of $2.4 million, R\u0026D expenses of $24.4 million, and a net loss of $26.1 million ($0.58 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and material business updates regarding clinical trial progress for lead candidate BGE-102.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:23:50.596323+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24597,"accession_number":"0001193125-26-335368","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BioAge Labs issued a press release on August 5, 2026 announcing its financial results for the second quarter ended June 30, 2026, including collaboration revenue of $2.4 million, R\u0026D expenses of $24.4 million, and a net loss of $26.1 million ($0.58 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and material business updates regarding clinical trial progress for lead candidate BGE-102.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:23:50.596323+00:00","company_name":"BioAge Labs, Inc.","ticker":"BIOA","filing_date":"2026-08-05"}]}